WO2004058966A1 - 肝臓疾患診断用マーカー蛋白質およびそれを利用した肝臓疾患診断方法 - Google Patents
肝臓疾患診断用マーカー蛋白質およびそれを利用した肝臓疾患診断方法 Download PDFInfo
- Publication number
- WO2004058966A1 WO2004058966A1 PCT/JP2003/016600 JP0316600W WO2004058966A1 WO 2004058966 A1 WO2004058966 A1 WO 2004058966A1 JP 0316600 W JP0316600 W JP 0316600W WO 2004058966 A1 WO2004058966 A1 WO 2004058966A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- amino acid
- liver disease
- acid sequence
- diagnosis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
Definitions
- the present invention has been found that a plurality of serum proteins that have been found to be usable as marker proteins for diagnosing liver disease that increase or decrease with habitual drinking and are thus found.
- the present invention relates to a method for diagnosing the possibility of developing liver disease, liver disease, prognosis of liver disease, etc. of problem drinkers by detecting or quantifying presence or absence.
- T / -GTP is the most widely measured marker of habitual drinking, but even if the drinker shows a high GGT, the value does not necessarily correlate with the severity of liver damage or the cumulative amount of drinking.
- GGT GGT
- CDT sugar-deficient tontransferrin
- Acetaldehyde the first generation product of ethanol, is highly reactive and forms various types of adducts with various proteins. For example, acetaldehyde -Attempts have been made to detect hemoglobin adducts by HPLC and the like. Some of them are expected to be interesting markers, such as HbAlc in diabetes, where the amount of alcohol used can be traced back in the past, but the sensitivity is difficult and it has not been put into practical use.
- Habitual drinking is one of the two major causes of chronic f disorders. In Japan, only 10 to 15% of cases are caused by pure alcohol only. However, this data was obtained mainly for university hospitals, and given the existence of alcoholism, which is expected to exceed 2 million, there is an opportunity to visit a medical institution. It is anticipated that there will be a large number of patients with alcoholic liver disease who have no alcoholic habits, and habitual drinking is also an exacerbation factor such as cerebral hemorrhage, hypertension, gout, etc. However, as described above, there is no definitive sensitivity and specificity among so-called drinking markers that currently exist, and it is required to search for new markers.
- Two-dimensional protein electrophoresis is a common method for comprehensive expression protein analysis, but it is difficult to detect low molecular weight proteins or peptides.
- a protein chip technology that combines surface enhanced laser desorption ionization (SELDI) and a flying mass spectrometer has been developed by Ciphergen in the US, and clinical applications such as the detection of a new moon serious tumor marker have begun. Therefore, it is required to search for new markers comprehensively using these proteomics technologies. Disclosure of the invention
- An object of the present invention is to find a novel marker capable of screening a liver disease of a problem drinker or the like early and accurately, to establish a measurement system thereof, and to make it useful for medical treatment.
- the present inventors have completed the present invention.
- the present inventors applied protein chip technology and used serum samples collected over time in alcohol-dependent patients who were hospitalized for the purpose of stopping drinking, and new serum that increased or decreased with habitual drinking The protein was successfully identified.
- the inventors have found that these serum proteins can be used as liver disease diagnostic marker proteins, thereby completing the present invention. It was.
- the present invention is a degradation product of human fibrinogen-E chain, a protein having a molecular weight of 5,900 (5.9 kDa protein), and a degradation product of apolipoprotein All (Apolipoprotein All).
- the present invention relates to a marker protein for liver disease diagnosis selected from mutants having a function as a marker protein for liver disease diagnosis.
- the present invention provides a method for detecting the presence or the amount of the marker protein for liver disease diagnosis in a sample obtained from a patient suspected of having liver disease, or measuring the amount of the marker protein.
- the present invention relates to a method for diagnosing prognosis.
- the present invention provides a novel protein having an amino acid sequence of SEQ ID NO: 1 in the sequence listing, or a variant thereof, which has the same function as a marker protein for liver disease diagnosis similar to the protein,
- the present invention relates to a protein having a homology of at least% or a variant that is a protein having an amino acid sequence in which one to several amino acid residues are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 1.
- the present invention is a novel protein having the amino acid sequence of SEQ ID NO: 2 in the sequence listing or a variant thereof, which has the same function as a marker protein for diagnosing liver disease similar to the protein, and is 90%
- the present invention relates to a protein having the above homology or a variant having an amino acid sequence in which one to several amino acid residues are deleted, substituted or appended in the amino acid sequence of SEQ ID NO: 2.
- the present invention relates to a method for measuring the above-mentioned proteins or variants thereof, and relates to a method for measuring by an immunoassay using an antibody against these proteins or variants.
- Figure 1 shows the measurement results of serum from alcoholic liver injury patients using Ciphergen protein chip system and SAXII chip. 28 kDa protein over time from admission, 1 week, 3 months after decrease in peak height It can be seen that (Apolipoprotein AI) gradually decreases from the serum.
- Fig. 2 shows the measurement results of sera from patients with alcoholic liver injury measured using the WCXII chip in the same way as in Fig. 1. It can be seen that the blood concentrations of (1) 5.9 kDa protein and (2) 7.8 kDa protein increased over time from hospitalization to treatment.
- Fig. 3 shows the measurement results of healthy human serum measured using a WCXII chip in the same way as Fig. 1.
- the 5.9 kDa protein and (2) the 7.8 kDa protein show a certain high value.
- Fig. 4 shows the results of electrophoresis of 7.8 kDa protein and 28 kDa protein by SDS-PAGE. It can be seen that the target protein is contained in the sample.
- Figure 5 shows the mass spectrometry and HPLC data of the synthesized 5.9 kDa protein. It can be seen that the mass spectrometry value agrees with the theoretical value.
- Figure 6 compares the synthesized 5.9 kDa protein and non-drinking patient serum data using the WCXII protein chip array using the Ciphergen protein chip system. Both had the same behavior with a peak at 5.9 kDa.
- Fig. 7 shows the serum samples of healthy subjects and patients with various alcohol consumption, and the size of the peak of the prote from Ciphergen. It has been revealed that the peak becomes smaller depending on the amount of alcohol consumed.
- Figure 8 shows the absorbance measured by the EIA method (sandwich ELISA method) using samples containing various concentrations of the 5.9 kDa protein.
- the horizontal axis shows the concentration of 5.9 kDa protein, and the vertical axis shows the measured absorbance. 5.
- An increase in absorbance is observed depending on the concentration of the 9 kDa protein. This indicates that the concentration of the 5.9 kDa protein in the sample can be measured by the EIA method.
- a protein that has been found to be usable as a marker protein for liver disease diagnosis according to the present invention is a degradation product of human fibrinogen ⁇ - ⁇ chain.
- a protein with a molecular weight of 5,900 hereinafter referred to as 5.9 kDa protein
- a degradation product of apolipoprotein all Polipoprotein All
- a protein with a molecular weight of 7,800 hereinafter referred to as 7.8 kDa protein
- Apolipoprotein AI is a protein with a molecular weight of 28,000 (hereinafter referred to as 28 kDa protein). These 5.9 kDa protein, 7.8 kDa protein, and 28 kDa protein are proteins having amino acid sequences shown in SEQ ID NOs: 1, 2, and 3, respectively.
- the 9 kDa protein is a degradation product of human Fibrinogen a ⁇ E Chain, a protein consisting of 54 amino acids, and its theoretical molecular weight is 5904.2.
- the 8 kDa protein is a degradation product of human Apolipoprotein All, a protein consisting of 68 amino acids, with a theoretical molecular weight of 7753.8.
- the 28 kDa protein is Apolipoprotein AI, a protein consisting of 243 amino acids with a theoretical molecular weight of 28078.
- the 5.9 kDa protein and the 7.8 kDa protein are the first in the present invention to clarify the clinical significance in the presence of blood, liver damage, etc. These are novel proteins and new marker substances.
- Apolipoprotein AI, a 28 kDa protein is a known protein that has been clinically measured after its clinical significance in lipid metabolism has been established.
- the 5.9 kDa protein, the 7.8 kDa protein and the 28 kDa protein that have been found to function as a marker protein for liver disease diagnosis according to the present invention are limited to those having the amino acid sequences shown in the sequence listing.
- a marker for liver disease diagnosis may be a variant of those proteins having a function as a protein. That is, there is a high possibility of degradation by various types of endo and exoproteases, especially in blood and tissues, and it should be fully considered that there are changes in the total length of amino acids and the length of sequences. In recombinant protein production, it is a common practice to have amino acid mutations that do not change the antigenicity as much as possible in order not to reduce the expression efficiency.
- the amino acid sequences of the 5.9 kDa protein, 7.8 kDa protein and 28 kDa protein of the present invention are 90% or more homologous (herein, homology means amino acid identity). It may be a variant thereof which is a protein having Those Ami There is no problem even if the length of the nonacid sequence is changed within 15%, and the case where it has a function as a marker protein for liver disease diagnosis is included in the present invention. A protein having a homology of 95% or more is preferable, and a protein having a homology of 98% or more is more preferable.
- the amino acid sequence homology is based on the search method described in the known software, for example, the method of Wilber, WJ and Lipman, D. J et al.
- mutants of the 5.9 kDa protein, 7.8 kDa protein and 28 kDa protein, which are the monthly marker proteins for diagnosing diseases according to the present invention include amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively.
- a protein having an amino acid sequence in which one to several amino acid residues are deleted, substituted, or added, and having the same function as a marker protein for liver disease diagnosis may be used. Examples of such mutants include:
- Examples include proteins in which less than 10% of amino acid residues are modified, preferably proteins in which less than 5%, more preferably less than 2% of amino acid residues are modified. Modification of amino acid residues can be introduced as amino acid mutations by genetic techniques well known to those skilled in the art. Mutants that have undergone known modifications such as post-translational modification, phosphorylation, acetylation, and chain addition are also included in the scope of the present invention.
- liver protein diagnosis marker protein found by the present invention described above, it becomes possible to diagnose liver diseases. That is, in the sample obtained from a patient suspected of having liver disease, the presence / absence of the above-mentioned monthly protein marker for diagnosis of disease is detected or the amount thereof is measured to determine the possibility of developing liver disease, the prognosis of liver disease or liver disease. Can be diagnosed.
- Samples that can be used in this effort include serum, plasma, blood, and urine collected from patients suspected of having liver disease.
- Any currently known method can be employed to detect the presence or absence of the marker protein for liver disease diagnosis of the present invention or to measure the amount thereof. Examples include mass spectrometry, immunoassay, electrophoresis, liquid chromatography (LC), and gas chromatography (GC).
- Laser ionization time-of-flight mass spectrometer For mass spectrometry, laser ionization time-of-flight mass spectrometer (LDI-TOF MS) The method performed by is mentioned.
- Laser ioni time-of-flight mass spectrometers include Surface Enhanced Laser Desorption /
- Time-of-flight mass spectrometer (SELDI-TOF MS method), Matrix—Assisted Laser Desorption / Ionization, ⁇ ⁇ time-type mass spectrometer (MALDI TOF MS method) .
- the protein “Biology System II / Mass” spectrometer developed by Ciphergen (Ciphergen Biosystems, Inc) can be used.
- This machine is an open chip technology combining SELDI (surface enhanced laser desorption ionization; and flight-type 3 ⁇ 4-quantity analysis. The details are detailed in W0 01/25791 A2 and JP 2001-28122.
- SELDI-TOF MS method the sample is usually pre-treated and then adsorbed to the chip and attached to the SELDI-T0F MS mass meter.
- a chip capable of adsorbing the marker protein for liver disease diagnosis of the present invention is a chip capable of adsorbing the marker protein for liver disease diagnosis of the present invention.
- chips modified with functional groups having affinity for proteins such as hydrophobicity and ion exchange (also known as chemical chips) U)
- a chip fixed I human antibodies against the protein of interest biochemical chips.
- mass spectrometry methods include mass spectrometry using the ESI method (Electrospray Ionization).
- ESI method Electronuclear Ionization
- Examples of the immunoassay method include a method of preparing a polyclonal antibody or a monoclonal antibody against the liver disease diagnosis marker protein of the present invention and measuring a conventionally known protein.
- Examples of such immunoassays include enzyme immunoassay (EIA method), immunoturbidimetric assay (TIA method), latex immunoaggregation (LATEX method), electrochemiluminescence method, and fluorescence method. it can.
- the immunochromatography method and the method using test paper are also effective. These methods are all well known to those skilled in the art. .
- antibodies that can be used in the above immunoassay include polyclonal and monoclonal antibodies prepared by methods that are already widely used. These antibodies can be obtained by using a purified protein derived from human blood, specifically, 28 kDa protein, 7.8 kDa protein, and 5.9 kDa protein as an immunogen (antigen). These proteins for producing antibodies may be obtained by purification from human blood, but may also be obtained by chemical synthesis using known peptide synthesis techniques. Not limited to this, a produced protein such as cultured cells can also be used as an antigen. Furthermore, the use of full-length recombinant proteins produced by genetic engineering, mutants thereof, or parts thereof is a conventional method and can be used.
- Monoclonal antibodies are antibodies derived from the various antigens described above, such as 28 kDa protein, 7.8 kDa protein, 5.9 kDa protein, ie, a marker protein, etc. Produced by a hybridoma obtained by fusing the production cells with bone marrow tumor cells.
- Hypridoma can be obtained by the following method. That is, the antigen obtained as described above, for example, a marker protein is mixed together using Freund's complete, incomplete adjuvant, aluminum hydroxide adjuvant, pertussis adjuvant, etc., to prepare a sensitive adjuvant solution. Immunize mice, rats and other animals by intraperitoneal subcutaneous or caudal vein administration every 1 to 3 weeks. Although the sensitizing antigen amount is the during normal l ⁇ g ⁇ 100 mg, generally preferably about 50 mu ⁇ . The number of immunizations is generally 2-7, but various methods are known. Next, antibody-producing cells derived from the spleen etc.
- fusion can be performed by using polyethylene glycol (PEG) according to the conventional method of Kohler and Milstein (Nature. 256, 495. 1975), which is already known per se. Fusion can also be performed by Sendai virus or electrofusion.
- PEG polyethylene glycol
- a method of selecting a hybridoma that produces an antibody that recognizes the marker protein from the fused cells can be performed as follows. That is, it is made from the fused cells by cells that survive in HAT medium and HT medium by limiting dilution. Select a high-pridoma from the colonies that appear. If the colony culture supernatant made of fused cells covered with 96-wells contains antibodies to the marker protein, the supernatant is placed on the assembly plate with the marker protein immobilized on the plate.
- a monoclonal antibody-producing clone against the marker protein can be selected by an ELISA method in which a secondary labeled antibody such as an anti-mouse immunoglobulin-HRP labeled antibody is reacted after the reaction.
- enzymes such as alkaline phosphatase, fluorescent substances, radioactive substances, etc. can be used as the labeling substance for the labeled antibody.
- enzymes such as alkaline phosphatase, fluorescent substances, radioactive substances, etc.
- BSA which is a blocking agent
- hybridomas CN-1 and CN-2 established by the present inventors are clones that specifically recognize the human 5.9 kDa protein, and can be mentioned as preferred examples.
- Hypri Dorma CN-1 and CN-2 are registered in the National Institute of Advanced Industrial Science and Technology (IP0D), National Institute of Advanced Industrial Science and Technology (IP0D), 1-chome Tsukuba 1-chome, Ibaraki, 305_8566, Japan. It was deposited on December 12, 2003 under the accession number IP0D FERM BP-0856 and on December 12, 2003 under the accession number IPOD FERM BP-08565.
- the hybridoma can be cultured in a medium usually used for cell culture, such as ⁇ - ⁇ , RPMI1640, ASF, S-clone, and the monoclonal antibody can be recovered from the culture supernatant.
- a medium usually used for cell culture such as ⁇ - ⁇ , RPMI1640, ASF, S-clone
- the monoclonal antibody can be recovered from the culture supernatant.
- An animal from which a hyperpridoma is derived or a nude mouse is treated in advance with pristane, and ascites is retained by intraperitoneal injection of cells into the animal, and the monoclonal antibody can be recovered from the ascites.
- a usual method can be used as a usual method can be used. For example, salting-out method using ammonium sulfate, sodium sulfate, etc., chromatography, ion exchange chromatography, affinity chromatography using protein A, etc. can be mentioned.
- the monoclonal antibody according to the present invention purified by the above method can accurately measure 28 kDa protein, 7.8 kDa protein or 5.9 kDa protein in a sample. it can. 28 kDa protein in a sample by EIA method, 7. As a method of measuring the 8 kDa protein or 5. 9 kDa protein, the method known per se, one or more monoclonal antibodies against a marker protein as an antibody It can be done by using. Examples are described below. First of all, directly or indirectly to a solid phase such as polystyrene, polypropylene, polycarbonate, polyethylene, nylon, polymetatalylate, etc. Bind monoclonal antibody.
- a solid phase such as polystyrene, polypropylene, polycarbonate, polyethylene, nylon, polymetatalylate, etc. Bind monoclonal antibody.
- the amount of sensitizing antibody is usually in the range of 1 ng to 100 mg / ml.
- a sample is added to the monoclonal antibody bound to the solid phase by physical bonds, chemical bonds, or affinity, and allowed to react. After reacting for a certain period of time, the solid phase is washed and the corresponding secondary labeled antibody (for example, anti-28 kDa protein secondary labeled antibody, anti-7.8 kDa protein secondary labeled antibody, anti-5.9 kDa protein secondary labeled (Antibody) and add a second reaction. Wash the solid phase again and add DAB chromogenic substrate.
- HRP is used as the labeling substance
- known DAB, TMB, etc. can be used as the substrate, and the labeling substance is not limited to this.
- the labeling substance is not limited to this.
- labeled metals such as europium, FITC, rhodamine, Texas Red,
- Examples include various identifiable substances such as various chemical and biological fluorescent substances such as Alexa and GFP and radioactive substances such as 32 P and 51 Cr.
- the marker protein can be measured by electrophoresis, liquid chromatography (LC) method, gas chromatography (GC) method and the like. These methods are already well known to those skilled in the art, and those known methods can be employed as they are.
- the diagnostic method of the present invention can diagnose, for example, the possibility of habitual drinkers and problem drinkers developing liver disease, and diagnose liver diseases caused by drinking, such as hepatitis and cirrhosis. It is also possible to diagnose normal liver diseases. Furthermore, liver disease It is also possible to diagnose the course of treatment.
- the diagnostic method of the present invention is particularly suitable for diagnosing alcoholic liver disorder, alcohol dependence and the like. The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.
- SAXII protein chip array Using informed patient serum, using SAXII protein chip array (Ciphergen Biosystems, Inc) to identify a new liver injury marker in serum searched.
- the SAXII chip is a strong anion exchange chip and has the characteristic of binding negatively charged substances in the specimen.
- serum of alcoholic liver disorder patients immediately after hospitalization and 1 week after alcohol cessation, 3 months, and normal subjects were used.
- the protein chip array experimental procedure is briefly described below. Serum samples were diluted 10-fold with 8M urea (SIGMA) / 1% CHAPS (SIGMA) solution. After treatment on ice for 10 minutes, further dilute 10-fold with 50 mM Tris (SIGMA) buffer (pH 9.0) and centrifuge at 4,000 rpm for 5 minutes. Used as a diluted sample.
- SIGMA 8M urea
- SIGMA mM Tris
- the SAXII chip was attached to the Bioprocessor for experiments. Bioprocessor is a plastic adapter with a hole that makes three-dimensional wells easily on a metal chip. A large amount of diluted sample can be applied by this method.
- PAPen (Zymed) is used to enclose the spot where the protein is adhered, and 0.5 ⁇ of saturated sinapinic acid (Ciphergen Biosystems, Inc) / 50% (Wako) /0.5% TFA (Wako) solution was added twice.
- the resulting protein chip array was “taken” by the Protein Biology System II * Mass Spectrometer (Iphergen Biosystems, Inc.).
- Fig. 1 shows the measured data of serum from patients with typical alcoholic liver injury.
- the molecular weight of the protein in the sample desorbed from the SAXII protein chip can be represented on the horizontal axis, and the peak reflecting the amount of analyte reaching the detector at that molecular weight can be represented on the vertical axis. Therefore, as is clear from Fig. 1, the data on admission of patients with ananolic hepatopathy showed a protein peak with a molecular weight of 28 kDa, but it was seldom observed after admission. Therefore, it was found that liver disease can be diagnosed using this 28 kDa protein as an index.
- WCXII protein chip array Identification of marker protein for liver disease diagnosis using WCXII protein chip array
- WCXII protein chip array (Ciphergen Biosystems, Inc) .
- the WCXII chip is a Weak Cation Exchange Chip and has the feature of binding positively charged substances in the specimen.
- Serum samples were diluted 10-fold with 8M urea (SIGMA) / 1% CHAPS (SIGMA) solution. After treatment on ice for 10 minutes, further dilute 10-fold with 50 mM sodium acetate (SIGMA) buffer (pH 6.5), and centrifuge at 4,000 rpm for 5 minutes. Used as a diluted sample.
- SIGMA sodium acetate
- the WCX II chip is attached to the Bioprocessor for experimentation. First, 150 ⁇ l of 50 mM sodium phosphate buffer (pH 6.5) is added to the well-shaped chip and washed on a shaker for 5 minutes. It was.
- Fig. 2 shows the measured data of serum from patients with typical alcoholic liver injury
- Fig. 3 shows the measured data of normal subjects.
- the normal data in Fig. 3 has a large peak of molecular weight 5,900 Da (5.9 kDa protein) and molecular weight 7,800 (7.8 kDa protein).
- the data immediately after admission for patients with alcoholic liver disease in Fig. 2 were found to have few peaks.
- the peaks for the 5.9 kDa protein and the 7.8 kDa protein increase with the treatment, indicating a good therapeutic effect. These proteins were found to be markers for liver disease diagnosis.
- Polyacrylamid Gradient Gel (Perfect NT bel System Products) was used at 10 mA.
- the gel panda was cut out and the peptides were separated by the In-Gel Digestion method. Briefly, gel pieces were washed twice and then trypsinized overnight at 35 ° C. The trypsinized sample was then purified by reverse phase HPLC. The purification conditions were gradient elution using a TSK gel 0DS-80Ts QA (T0S0H) column with 0.1% TFA and 0.09% TFA 90% acetonitrile.
- the internal amino acid sequence of the resulting 28 kDa protein fragment was determined.
- the amino acid sequence of the 28 kDa protein is shown in SEQ ID NO: 3 in the sequence listing. Analysis of the amino acid sequence of the 28 kDa protein fragment revealed that
- Biotech AB used the HiTrap CM Sepharose FF column and purified the serum sample under the conditions of 50 mM Ammonium Acetate buffer and a flow rate of 2 ral / min.
- the target 7.8 kDa protein was purified.
- the fraction in which the 7.8 'kDa protein was confirmed by protein chip experiment was confirmed by electrophoresis.
- Sample serum was mixed with 2X sample buffer containing SDS at a ratio of 1: 1, treated at 90 ° C for 2 minutes, and then used. Electrophoresis was performed at 10 mA using 15-25% Polyacrylamide Gradient Gel. (2) As shown in lanes 2 and 3 in Fig. 4, a band was confirmed at 7.8 kDa by Kumasi-brilliant pull-staining.
- the fraction containing almost 7.8 kDa protein is concentrated, and the target 7.8 kDa band is excised from the gel by SDS-PAGE in the same manner as in Example 3 of the 28 kDa protein above, and the In-Gel Digestion method is used.
- the peptides were separated by This method is the same as in Example 3, but briefly, the gel pieces are washed twice and then trypsinized at 35 ° C.
- the trypsinized sample was then purified by reverse phase HPLC.
- the purification conditions were gradient elution with 0.1% TFA and 0.09% TFA 90% acetonitrile using a TSK gel 0DS-80Ts QA (T0S0H) column.
- the amino acid sequence of the purified 5.9 kDa protein was determined to be a degradation product of human Fibrinogen-E Chain. Since the full-length human Fibrinogen ⁇ - ⁇ Chain has a molecular weight of 72488.3, the 5.9 kDa protein was found to be a degradation product of human Fibrinogen aE Chain. is there. 5.
- the amino acid sequence of the 9 kDa protein is shown in SEQ ID NO: 1.
- the protein of that sequence was completely chemically synthesized.
- the molecular weight of the 54-amino acid protein synthesized was 59904.1, which was consistent with the theoretical value (Fig. 5).
- the synthetic protein was used for comparison with actual samples.
- the experiment was performed using the same WCXII protein chip array (Ciphergen Biosystems, Inc) as in Example 2, and a synthetic protein at a concentration of 100 ng / mL was reacted as a sample and compared with actual serum. The result is shown in FIG.
- the peak of the synthetic protein behaved in a manner consistent with the 5.9 kDa protein of the serum sample. From these results, the 5.9 kDa protein in the serum is the amino acid sequence shown in SEQ ID NO: 1. Was confirmed.
- Marker protein for liver disease diagnosis of the present invention and conventional hepatitis
- FDP and FDP-E were measured with LPIA-S500 (Diatron) at the specified parameter 1, and the reagents were Elpia FDP Latex, Elpia FDP-E Latex (Imperial Note that the protein chip measurement results are compared numerically from the peak, but the unit is AU (Arbitrary Units).
- Table 1 shows general laboratory tests in the serum of patients hospitalized for alcoholic liver injury, biochemical measurement markers (AST, GGT, TG) values, immune system measurement markers (Apo AI, Apo IV, FDP, FDP-E) ) Value, and the liver disease marker of the present invention by the protein chip method.
- the measurement result of Kerr protein is shown.
- FDP-E 5 900 Da and Apo All 7, 800 Da
- it is the marker protein for diagnosing liver disease of the present invention by the method using the same protein chip as in Example 2. 5.
- the measured values when measuring 9 kDa protein and 7.8 kDa protein are shown.
- the sixth column from the right of Table 1 shows the measured values when the 28 kDa protein, which is the marker protein for liver disease diagnosis of the present invention, was measured by the conventional method.
- Table 2 shows the 5.9 kDa protein (FDP-E 5, 900 Da) and 7.8 kDa protein (Apo All 7, 800 Da) proteins that are the marker proteins for liver disease diagnosis of the present invention in serum samples of healthy individuals. The measured value when measured by the tip method is shown.
- Table 3 shows the measured average values of 5.9 kDa protein and 7.8 kDa protein in hospitalized patients with alcoholic hepatopathy measured by the protein chip method.
- the results are shown in FIG. As a result, it was found that the peaks increased and decreased depending on the amount of alcohol consumed in all the novel marker proteins for liver disease diagnosis.
- Alcohol consumption The 5.9 kDa protein decreased in a manner dependent on the amount of alcohol consumed, and decreased to a level that was almost undetectable in the experimental group that was drinking 3 groups.
- the 5.9 kDa protein was found to change depending on the amount of alcohol consumed, and was a marker that could be used sufficiently to estimate the amount of alcohol consumed. It was also found that it could be a marker for alcoholism.
- the resulting mixture was mixed with a mixture to prepare an emulsified suspension by the same procedure as in Freund's complete adjuvant band, and each mouse was sensitized. The same procedure was followed 2 weeks later, and the fourth round was fully synthesized as the final immunization. 5.9 kDa protein 50 // g / ml was prepared in phosphate buffer (pH 7.0) and administered via mouse tail vein injection. did.
- spleen cells were prepared by aseptically dispersing the spleen that had been surgically removed from mice sensitized with a synthetic 5.9 kDa protein under anesthesia with diethyl ether. Fusion was performed according to the method of Köhler and Milstein (Nature. 256, 495. 1975), and splenocytes and myeloma cells P3-X63-Ag8-Ul (P3U1) were used with polyethylene glycol (PEG4000) (MERK). Fused.
- the fused cells are dispersed in 10% FCS (INVITR0GEN) H-MEM (IRVINE) HAT (Cosmo Bio) medium and dispensed into 96-well microtiter culture plates (Sumitomo Bakelite) at 37 ° C and 5% CO 2 conditions. Cultured.
- the completed plate was washed 3 times with a phosphate buffer containing 0.05% Tween 20, then reacted with 100 ⁇ ⁇ of the culture supernatant, washed further, and then washed with the secondary antibody HRP-labeled anti-mouse immuno.
- a globulin antibody (Zymed) was added and reacted.
- the absorbance was measured at a measurement wavelength of 492 nm. Clones that became positive as described above were recloned by limiting dilution and the supernatant was checked again.
- Hypridoma CN-1 and CN-2 cells 1 x 10 'cells were treated with pristane (Aldrich) 0.5 ml Balb mice (CLEA Japan), 10 weeks old, female
- pristane Aldrich
- Balb mice CLA Japan
- ascites collected in the abdominal cavity of the mouse was surgically collected under jetyl ether anesthesia.
- ascitic fluid was used as a sample and confirmed by serial dilution by ELISA, a high concentration of monoclonal antibody was contained.
- the ascites was treated with 40% ammonium sulfate, dialyzed against PBS, and then CN-1 and CN-2 were purified using S-300.
- CN-1 and CN-2 showed a single band with a molecular weight of about 900,000 when non-reduced, and a band with a molecular weight of about 70,000 and two pandas of 25,000 when reduced with mercaptoethanol.
- the purified antibodies were approximately 10 mg or more per mouse for both CN-1 and CN-2, sufficient for industrial use.
- the plate was washed three times with a phosphate buffer containing 0.05% Tween 20, and the HRP-labeled CN-1 antibody, which is a secondary antibody, was added and reacted. After washing, add 100 ⁇ of 3 mg / ml o-phenylenediamine (OPD) (Nacalai tesque) citrate coloring solution, which is the coloring substrate of HRP. Jul was added, and the absorbance was measured at a measurement wavelength of 492.
- OPD o-phenylenediamine
- a standard curve for the measurement of synthetic 5.9 kDa protein was generated from the color development values of various concentrations of synthetic 5.9 kDa protein measured as described above, and the results shown in Fig. 8 were obtained. From Fig. 8, an increase in absorbance was observed depending on the concentration of the synthetic 5.9 kDa protein.
- the monoclonal antibodies CN-1 and CN-2 that recognize the 5.9 kDa protein have different recognition sites, the 5.9 kDa protein can be measured by using these antibodies in a sandwich ELISA method. found. Industrial use available
- the marker protein for diagnosing liver disease of the present invention is a non-responder in which a conventional hepatitis marker such as GGT is less reactive, or fatty liver caused by obesity, Even if the GGT shows a high value due to factors other than alcohol use such as drug addicts, it can be an index for accurately examining the treatment judgment effect of patients with liver disease resulting from alcohol consumption and grasping the status. In other words, GGT is low in specificity because it increases due to other factors such as continuous use of certain drugs other than alcohol drinking and obesity.
- the marker protein has the advantage that it can be expected to be specific because it does not change even with viral cirrhosis.
- the sample to be measured is a peptide that does not depend on biochemical enzyme function, so that the sample is handled well and the measurement reproducibility is good.
- the diagnostic method of the present invention can also diagnose, for example, the possibility that a habitual drinker and a problem drinker will develop liver disease. Liver diseases such as hepatitis and cirrhosis can also be diagnosed. Furthermore, it is possible to diagnose the course of treatment for such liver diseases.
- the diagnostic method of the present invention is particularly suitable for diagnosing alcoholic liver disorder, alcohol dependence and the like.
- the marker protein can be measured by a general-purpose EIA method, immunochromatography, or paper test paper. The fact that it can be easily diagnosed by these widely used methods is considered to be significant from the viewpoint of preventive medicine in the future even from the viewpoint of the current population of liver diseases.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Endoscopes (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03786267A EP1577385B1 (en) | 2002-12-24 | 2003-12-24 | Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same |
US10/538,916 US7517951B2 (en) | 2002-12-24 | 2003-12-24 | Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same |
JP2004562919A JP4196948B2 (ja) | 2002-12-24 | 2003-12-24 | 肝臓疾患診断用マーカー蛋白質およびそれを利用した肝臓疾患診断方法 |
AT03786267T ATE462001T1 (de) | 2002-12-24 | 2003-12-24 | Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit |
AU2003296085A AU2003296085A1 (en) | 2002-12-24 | 2003-12-24 | Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same |
DE60331857T DE60331857D1 (de) | 2002-12-24 | 2003-12-24 | Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit |
NO20052992A NO336459B1 (no) | 2002-12-24 | 2005-06-17 | Markørproteiner og in vitro metoder for diagnostisering av leversykdom og metoder for måling av protein. |
US12/379,904 US7781180B2 (en) | 2002-12-24 | 2009-03-04 | Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002371959 | 2002-12-24 | ||
JP2002-371959 | 2002-12-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10538916 A-371-Of-International | 2003-12-24 | ||
US12/379,904 Division US7781180B2 (en) | 2002-12-24 | 2009-03-04 | Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004058966A1 true WO2004058966A1 (ja) | 2004-07-15 |
Family
ID=32677218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/016600 WO2004058966A1 (ja) | 2002-12-24 | 2003-12-24 | 肝臓疾患診断用マーカー蛋白質およびそれを利用した肝臓疾患診断方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US7517951B2 (ja) |
EP (1) | EP1577385B1 (ja) |
JP (1) | JP4196948B2 (ja) |
CN (1) | CN100384996C (ja) |
AT (1) | ATE462001T1 (ja) |
AU (1) | AU2003296085A1 (ja) |
DE (1) | DE60331857D1 (ja) |
NO (1) | NO336459B1 (ja) |
WO (1) | WO2004058966A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006284389A (ja) * | 2005-03-31 | 2006-10-19 | Mcbi:Kk | タンパク質、部分タンパク質および/もしくは部分ペプチド、またはそれらのプロファイルに基づく体外診断システム |
WO2008105215A1 (ja) * | 2007-02-28 | 2008-09-04 | Nitto Boseki Co., Ltd. | アルコール性肝障害診断用マーカーペプチドおよびそれを利用したアルコール性肝障害診断方法 |
JP2009114092A (ja) * | 2007-11-02 | 2009-05-28 | Mcbi:Kk | 慢性肝炎、肝硬変、肝がんの分別診断のための新規バイオマーカーおよび該バイオマーカーを用いた慢性肝炎、肝硬変、肝がんの分別診断方法 |
WO2010087434A1 (ja) * | 2009-01-30 | 2010-08-05 | 財団法人 ヒューマンサイエンス振興財団 | 膵臓癌の検出法 |
WO2011052380A1 (ja) | 2009-10-28 | 2011-05-05 | 日東紡績株式会社 | 5.9kDaペプチドの免疫学的測定方法 |
WO2013141092A1 (ja) * | 2012-03-21 | 2013-09-26 | Tsuru Michiyo | 癌転移マーカー及びそれを用いた癌転移の診断方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2893136A1 (fr) * | 2005-11-10 | 2007-05-11 | Sanofi Aventis Sa | Procedes de diagnostic de maladies hepatiques et de criblage de molecules pour le traitement de ces maladies |
US7750018B2 (en) * | 2006-12-06 | 2010-07-06 | Tactical Therapeutics, Inc | Use of carboxiamidotriazole (CAI) orotate in macular degeneration |
JP2012501454A (ja) * | 2008-08-28 | 2012-01-19 | サルトリア・フアーマシユーテイカルズ・エル・エル・シー | 肝臓病学的有害事象のリスクのある患者を同定するためのスクリーニング法 |
CN102507941B (zh) * | 2011-10-25 | 2014-04-30 | 北京正旦国际科技有限责任公司 | 一种肝硬化免疫质谱检测试剂盒 |
CN102507936B (zh) * | 2011-11-09 | 2013-10-23 | 北京正旦国际科技有限责任公司 | 一种肝癌标志物多抗免疫质谱试剂盒 |
EP2786154B1 (en) | 2011-12-01 | 2017-11-01 | Roche Diagnostics GmbH | Nt-proanp and nt-probnp for the diagnosis of stroke |
CN109444405A (zh) * | 2018-10-10 | 2019-03-08 | 东南大学 | 一种基于荧光预猝灭和表面增强荧光效应的免疫检测方法 |
CN110157792A (zh) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用 |
CN116041506B (zh) * | 2023-01-05 | 2023-12-05 | 深圳上泰生物工程有限公司 | 糖缺失性转铁蛋白的单克隆抗体对及检测试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63237795A (ja) * | 1987-03-24 | 1988-10-04 | Otsuka Pharmaceut Factory Inc | アポリポタンパク質の製造法 |
WO1994016085A2 (en) | 1992-12-30 | 1994-07-21 | Zymogenetics, Inc. | Hybrid proteins having cross-linking and tissue-binding activities |
WO2001086304A2 (en) * | 2000-04-28 | 2001-11-15 | Bayer Aktiengesellschaft | Diagnostic of liver fibrosis with serum marker algorithms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639940A (en) * | 1994-03-03 | 1997-06-17 | Pharmaceutical Proteins Ltd. | Production of fibrinogen in transgenic animals |
CN1170943C (zh) * | 2000-10-20 | 2004-10-13 | 上海医药(集团)总公司 | 建立载脂蛋白a-i细胞靶标筛药系统及筛选升高密度脂蛋白药的方法 |
ES2226549B1 (es) * | 2002-12-18 | 2006-07-16 | One Way Liver Genomics, S.L. | Metodo para el diagnostico de esteatohepatitis no alcoholica (nash) mediante el empleo de marcadores moleculares. |
-
2003
- 2003-12-24 AT AT03786267T patent/ATE462001T1/de not_active IP Right Cessation
- 2003-12-24 WO PCT/JP2003/016600 patent/WO2004058966A1/ja active Application Filing
- 2003-12-24 DE DE60331857T patent/DE60331857D1/de not_active Expired - Lifetime
- 2003-12-24 JP JP2004562919A patent/JP4196948B2/ja not_active Expired - Lifetime
- 2003-12-24 CN CNB2003801075522A patent/CN100384996C/zh not_active Expired - Lifetime
- 2003-12-24 EP EP03786267A patent/EP1577385B1/en not_active Expired - Lifetime
- 2003-12-24 US US10/538,916 patent/US7517951B2/en active Active
- 2003-12-24 AU AU2003296085A patent/AU2003296085A1/en not_active Abandoned
-
2005
- 2005-06-17 NO NO20052992A patent/NO336459B1/no not_active IP Right Cessation
-
2009
- 2009-03-04 US US12/379,904 patent/US7781180B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63237795A (ja) * | 1987-03-24 | 1988-10-04 | Otsuka Pharmaceut Factory Inc | アポリポタンパク質の製造法 |
WO1994016085A2 (en) | 1992-12-30 | 1994-07-21 | Zymogenetics, Inc. | Hybrid proteins having cross-linking and tissue-binding activities |
WO2001086304A2 (en) * | 2000-04-28 | 2001-11-15 | Bayer Aktiengesellschaft | Diagnostic of liver fibrosis with serum marker algorithms |
Non-Patent Citations (3)
Title |
---|
NOMURA F ET AL: "Protein chip technology ni yoru aratana inshu marker no tansaku", ALCOHOL TO IGAKU SEIBUTSUGAKU, vol. 23, 20 September 2003 (2003-09-20), pages 11 - 14, XP002981574 * |
POYNARD T ET AL: "A simple biological index for detection of alcoholic liver disease in drinkers", GASTROENTEROLOGY, vol. 100, no. 5, 1991, pages 1397 - 1402, XP002981575 * |
W.J., LIPMAN, D.J. ET AL., PROC. NATL. SCI. USA, vol. 80, 1983, pages 726 - 730 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006284389A (ja) * | 2005-03-31 | 2006-10-19 | Mcbi:Kk | タンパク質、部分タンパク質および/もしくは部分ペプチド、またはそれらのプロファイルに基づく体外診断システム |
JP4597741B2 (ja) * | 2005-03-31 | 2010-12-15 | 株式会社Mcbi | タンパク質、部分タンパク質および/もしくは部分ペプチド、またはそれらのプロファイルに基づく体外診断システム |
WO2008105215A1 (ja) * | 2007-02-28 | 2008-09-04 | Nitto Boseki Co., Ltd. | アルコール性肝障害診断用マーカーペプチドおよびそれを利用したアルコール性肝障害診断方法 |
JP5419680B2 (ja) * | 2007-02-28 | 2014-02-19 | 日東紡績株式会社 | アルコール性肝障害診断用マーカーペプチドおよびそれを利用したアルコール性肝障害診断方法 |
JP2009114092A (ja) * | 2007-11-02 | 2009-05-28 | Mcbi:Kk | 慢性肝炎、肝硬変、肝がんの分別診断のための新規バイオマーカーおよび該バイオマーカーを用いた慢性肝炎、肝硬変、肝がんの分別診断方法 |
WO2010087434A1 (ja) * | 2009-01-30 | 2010-08-05 | 財団法人 ヒューマンサイエンス振興財団 | 膵臓癌の検出法 |
WO2011052380A1 (ja) | 2009-10-28 | 2011-05-05 | 日東紡績株式会社 | 5.9kDaペプチドの免疫学的測定方法 |
JP5585587B2 (ja) * | 2009-10-28 | 2014-09-10 | 日東紡績株式会社 | 5.9kDaペプチドの免疫学的測定方法 |
US9017959B2 (en) | 2009-10-28 | 2015-04-28 | Nitto Boseki Co., Ltd. | 5.9 kDa peptide immunoassay method |
WO2013141092A1 (ja) * | 2012-03-21 | 2013-09-26 | Tsuru Michiyo | 癌転移マーカー及びそれを用いた癌転移の診断方法 |
JPWO2013141092A1 (ja) * | 2012-03-21 | 2015-08-03 | 美智代 津留 | 癌転移マーカー及びそれを用いた癌転移の診断方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1577385A1 (en) | 2005-09-21 |
JP4196948B2 (ja) | 2008-12-17 |
NO336459B1 (no) | 2015-08-31 |
US20090275059A1 (en) | 2009-11-05 |
ATE462001T1 (de) | 2010-04-15 |
AU2003296085A1 (en) | 2004-07-22 |
CN1732261A (zh) | 2006-02-08 |
US7517951B2 (en) | 2009-04-14 |
NO20052992L (no) | 2005-09-14 |
NO20052992D0 (no) | 2005-06-17 |
CN100384996C (zh) | 2008-04-30 |
DE60331857D1 (de) | 2010-05-06 |
US7781180B2 (en) | 2010-08-24 |
US20060116504A1 (en) | 2006-06-01 |
EP1577385B1 (en) | 2010-03-24 |
JPWO2004058966A1 (ja) | 2006-04-27 |
EP1577385A4 (en) | 2006-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7781180B2 (en) | Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same | |
US8263347B2 (en) | Biomarker for diagnosis of liver disease | |
JP2006017745A (ja) | 免疫学的粒子凝集反応方法 | |
JPWO2009107170A1 (ja) | 抗crp抗体及びその利用 | |
JP2008175814A (ja) | 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット | |
NO338747B1 (no) | Immunanalysemetode | |
JPH1090268A (ja) | 免疫学的粒子凝集反応方法 | |
KR101338517B1 (ko) | 인간 간-카르복실에스터라제 1을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도 | |
FI119990B (fi) | N-peptidin kerrosimmuunimääritysmenetelmä | |
JPWO2009044561A1 (ja) | 抗proNT/NMNモノクローナル抗体 | |
WO2022023461A1 (en) | Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein | |
WO2019167874A1 (ja) | Apoa4に対するモノクローナル抗体、免疫学的測定方法及び測定用キット | |
EP1542011A1 (en) | Method of measuring collagen | |
JP6407990B2 (ja) | アウグリン免疫学的検定 | |
EP1213302A1 (en) | Specific antibody directed to active but not inactive hepatocyte growth factor activator (HGFA) | |
JP5117336B2 (ja) | 多発性硬化症またはnmoの検査マーカーの測定方法 | |
WO2023061388A1 (zh) | 半乳糖凝集素-3的免疫测定 | |
JP4013312B2 (ja) | モノクローナル抗体およびハイブリッド細胞 | |
JP5585587B2 (ja) | 5.9kDaペプチドの免疫学的測定方法 | |
JP2010071788A (ja) | アルコール常習者またはアルコール常習者における肝臓疾患を判定するためのペプチドマーカーの測定法 | |
JP2007230986A (ja) | 新規蛋白質ならびに治療、診断方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004562919 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006116504 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10538916 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003786267 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A75522 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003786267 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10538916 Country of ref document: US |